# Instructions for Obtaining Anesthesiology Continuing Medical Education (CME) Credit

CME Editors: Leslie C. Jameson, M.D., and Dan J. Kopacz, M.D.

Anesthesiology's Journal CME is open to all readers. To take part in Anesthesiology Journal-based CME, complete the following steps:

- 1. Read the CME information presented on this page.
- Read this month's article designated for CME credit (listed on the right) in either the print or online edition.
- 3. Register at http://education.asahq.org/2015-journal-cme. Nonmembers will be asked to provide payment.
- 4. Achieve a score of at least 50% correct on the six-question online journal CME quiz and complete the evaluation.
- Claim credit in 15-minute increments, for a maximum of 1 AMA PRA Category 1 Credit™ per journal article.

#### **CME Information & Disclosure**

**Purpose:** The focus of Anesthesiology Journal-based CME is to educate readers on current developments in the science and clinical practice of anesthesiology.

**Target Audience:** Anesthesiology Journal-based CME is intended for anesthesiologists. Researchers and other health care professionals with an interest in anesthesiology may also participate.

**Accreditation:** The American Society of Anesthesiologists is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

**CME Designation Statement:** The American Society of Anesthesiologists designates this Journal-based CME activity for a maximum of 1 *AMA PRA Category 1 Credit*™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

# Rates

Two options are available:

	ASA Member	Non-member
Annual Fee	\$0	\$120
Per Issue	\$0	\$20

Payment may be made using Visa or MasterCard.

Please direct any questions about Journal-based CME to: EducationCenter@asahq.org

Date of Release: May 2015 Termination Date: May 2018

# This Month's Anesthesiology Journal-based CME Article

Read the article by McLean *et al.* entitled "Dose-dependent Association between Intermediate-acting Neuromuscular-blocking Agents and Postoperative Respiratory Complications" on page 1201 and the accompanying editorial by Brull and Prielipp

entitled "Reversal of Neuromuscular Blockade: 'Identification Friend or Foe'" on page 1183 of this issue.

# **Learning Objectives**

After successfully completing this activity, the learner will be able to identify the risks of residual blockade after the administration of an intermediate-acting neuromuscular-blocking agent (NMBA), define the appropriate dose and timing of the administration of the acetylcholinesterase inhibitor neostigmine for reversal of an intermediate-acting NMBA, and select the most appropriate intermediate-acting NMBA.

### **Disclosures**

**Editor-in-Chief:** James C. Eisenach, M.D., receives consulting fees from Aerial BioPharma LLC and Cubist Pharmaceuticals, Inc.

**CME Editors:** Leslie C. Jameson, M.D., receives honoraria from GE Medical International and Masimo Corporation. Dan J. Kopacz, M.D., has an equity position in SoloDex, LLC.

**Authors:** Duncan J. McLean, M.B.Ch.B., Daniel Diaz-Gil, Cand. Med., Hassan N. Farhan, M.B.B.S., Karim S. Ladha, M.D., and Tobias Kurth, M.D., Sc.D., have reported no financial relationships with commercial interests. Matthias Eikermann, M.D., Ph.D., received funding for investigator-initiated research from Merck, Whitehouse Station, New Jersey, and from Massimo, Irvine, California. Dr. Eikermann has also filed a patent application for a new drug to reverse the effects of neuromuscular-blocking agents.

**Authors:** Sorin J. Brull, M.D., F.C.A.R.C.S.I. (Hon.), has reported to be a Member, Anesthesia Patient Safety Foundation Executive Committee and Board of Directors, and shareholder in ADBV (Amsterdam, The Netherlands), a medical device company. Richard C. Prielipp, M.D., M.B.A., F.C.C.M., has reported to be a Member, Anesthesia Patient Safety Foundation Executive Committee and Board of Directors.

**ASA Staff:** Kari L. Lee, Editorial Manager, has reported no financial relationships with commercial interests. Ginger Yarger, Editor, has an equity position in Merck & Co.

## **Resolution of Conflicts of Interest**

In accordance with the ACCME Standards for Commercial Support of CME, the American Society of Anesthesiologists has implemented mechanisms, prior to the planning and implementation of this Journal-based CME activity, to identify and resolve conflicts of interest for all individuals in a position to control content of this Journal-based CME activity.

#### **Disclaimer**

The information provided in this CME activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a health care provider relative to diagnostic and treatment options of a specific patient's medical condition.